Jefferies downgraded Lava Therapeutics (LVTX) to Hold from Buy with a price target of $1.50, down from $3, after the company entered into an agreement to be acquired by XOMA Royalty (XOMA) for between $1.16 and $1.24 per share in cash.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVTX: